Celldex Therapeutics (CLDX) is the lead sponsor of 8 active clinical trials listed on ClinicalTrials.gov[4], including 4 Phase 3[1], 2 Phase 2[2], 2 Phase 1[3].
Trial NCT07256392[5] evaluates barzolvolimab in Chronic Spontaneous Urticaria with a target enrollment of 1370 participants. Trial NCT06445023[6] evaluates barzolvolimab in Chronic Spontaneous Urticaria with a target enrollment of 963 participants. Trial NCT06455202[7] evaluates barzolvolimab in Chronic Spontaneous Urticaria with a target enrollment of 976 participants.
No Form 4 insider filings for CLDX were recorded at the SEC in the past 30 days[8].
Sources
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov (2026-04-11) ↗
- ClinicalTrials.gov · NCT07256392 (2026-03-31) ↗
- ClinicalTrials.gov · NCT06445023 (2026-03-25) ↗
- ClinicalTrials.gov · NCT06455202 (2026-03-25) ↗
- SEC EDGAR · 0000744218 (2026-04-11) ↗